Ignite Creation Date:
2025-12-25 @ 1:16 AM
Ignite Modification Date:
2026-01-01 @ 3:32 AM
Study NCT ID:
NCT05159193
Status:
RECRUITING
Last Update Posted:
2024-02-02
First Post:
2021-11-25
Is NOT Gene Therapy:
True
Has Adverse Events:
False
Brief Title:
Neoadjuvant Treatment Pegylated Liposomal Doxorubicin Plus Cyclophosphamide Sequential Docetaxel Plus Trastuzumab and Pertuzumab Versus Docetaxel Plus Carboplatin Combined With Trastuzumab and Pertuzumab in HER-2 Positive Breast Cancer
Sponsor:
Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University
Organization:
Key Dates - Follows AllAPIJSON File Order
Start Date:
2021-12-20
Start Date Type:
ACTUAL
Primary Completion Date:
2024-10-30
Primary Completion Date Type:
ESTIMATED
Completion Date:
2028-01-31
Completion Date Type:
ESTIMATED
First Submit Date:
2021-11-25
First Submit QC Date:
None
Study First Post Date:
2021-12-16
Study First Post Date Type:
ACTUAL
Results First Submit Date:
None
Results First Submit QC Date:
None
Results First Post Date:
None
Results First Post Date Type:
None
Results First Post QC Date:
None
Results First Post QC Date Type:
None
Disp First Submit Date:
None
Disp First Submit QC Date:
None
Disp First Post Date:
None
Disp First Post Date Type:
None
Last Update Submit Date:
2024-01-31
Last Update Post Date:
2024-02-02
Last Update Post Date Type:
ACTUAL